Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Scandion Oncology, Audiocast with teleconference, Q2'24

By Inderes8/29/2024, 9:00 AM
Scandion Oncology

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Francois Martelet, MD
00:00 - 06:50

Thank you very much and welcome again to this Q2 2024 report. Next slide, please. Right. So this is a disclaimer that we will not go through. Next one. All right. Today, we will go through the clearest data available. Basically, we will review the performance. This will be presented by our CFO, Johnny. Then, I will conclude this call with the near-term milestones of oncology. Right. Shall we have the next slide, please? Right. So, today the speakers, as I mentioned earlier, are myself as the CEO and Johnny, our CFO. Next slide. Right. So, today is an important call. The reason being that we have fully enrolled our patients in the current CORIST trial. Furthermore, we have achieved the MTD and consequently, we are in the process of finalizing the analysis of the full set of data from our CORIST clinical trial. So that's an important milestone that we, as Scandion Oncology, have achieved over the last few months. And I will come back to that. With regard to PANTAX, we have released the data actually in H1 of this year. Regarding gastric cancer, we have also released compelling preclinical data, and we are ready to proceed to Phase 1b/2a with regard to our other asset, which is SCO-101. We have decided, mainly due to financial constraints, to pause further development. From a preclinical perspective, these compounds still show potential. It means that we have decided to put the development of this compound on hold. Right. So let's move to the next slide, please. Right. So, regarding the CORIST Part Three, what have we basically achieved? The last cohort has indeed shown significant tumor reduction, which is defined as more than 30% tumor shrinkage. This was observed in a limited number of patients. Actually, two out of six who have been treated with a four-day schedule using FOLFIRI. We have used the dose of 250mg of SCO-101, and the tumor reduction in a recent study was actually as much less if you look at the percentage. While working with a limited number of patients, However, the tumor shrinkage that we have observed is significant. We have also observed an exciting clinical benefit rate of 76% after eight weeks. And if you compare it to historical controls, we are talking about a rate of 11 to 16%. Again, this is with a limited number of patients, a limited cohort. However, we believe there is some significance here, encouraging Part Two. We had a clinical benefit rate of about 42%, which was even more significant. We have a promising median overall survival close to eight months and the median progression-free survival around four months. Obviously, we are waiting for further data to mature. This is a classic case in oncology, and we expect to have even better data in a couple of months from now. Also, if we look at historical studies comparing minimum overall survival and median progression-free survival, we are able to show some better data. Another important point is the biomarker. So we've been able to identify UGT1A1 as a potential biomarker, especially with the wild type colorectal cancer patients. And this is certainly an important aspect for future development, because as we know, regulatory bodies now require a biomarker in order to better stratify patients and potentially get an approval, specifically talking about the FDA, but also in Europe. Right. Uh, shall we move to the next slide, please? Well, if we could summarize what we have done over the last few months and even years with regard to queries, we've been able to demonstrate a good safety and tolerability profile for our drug SCO-101. We have been able to show some partial responses in two patients in the last cohort of six patients, with some significant and impressive overall survival ranging between 8 and 10 months. That significant increase in overall survival is even better, is even enhanced if we look at patients expressing wild type UGT1A1, colorectal cancer patients, we are moving up to 13 months. Right. And the last progress that we have been able to show over the last quarter is actually the MTD. So, we've been able to establish an MTD (Maximum Tolerated Dose) for the four day regimen of our compound, SCO-101, combined with FOLFIRI at a 50% dosage and 100% efficacy. So overall, you know, if I look at and could summarize the dataset of queries from 1 to 3, the data is very encouraging. We have an active drug and therefore believe it will be extremely worthwhile to continue the development of this drug.

Unknown 1
06:51 - 06:51

Future.

Francois Martelet, MD
06:51 - 07:05

Settings. Phase 2b/3, potentially. Right, next slide, please. Johnny, would you take over, please?

Johnny Stilou, MSc
07:06 - 08:16

Yes, certainly. And thank you, François. As we state, our results for the quarter were in line with our expectations. The quarter showed a loss of 7.1 million Danish kroner. This is compared to a loss of 8.7 million Danish kroner in the same quarter of last year. Our cash position in June showed a position of 26.9 million Danish Kroner. This reflects the completed rights issue in June, which gave us net proceeds of 14.3 million Danish kroner. With these funds in total, our operations are fully funded into Q4 of 2025. On the next slide, as shown here, our quarterly expenses have once again been reduced compared to the previous quarter. Our quarterly costs will continue to decrease throughout 2024 and 2025 as a result of our very strict cost control. But now I will give the word back to discuss Phase One.

Francois Martelet, MD
08:18 - 13:55

Thank you, Johnny, and thank you for your good cash management. Right. So let's look at the next milestones. You can see at the top of the slide that we are expecting to release data from the CORIST part three later this year, concerning overall survival and median progression-free survival. Median progression free survival is key. We have recently reached our MTD (Maximum Tolerated Dose). This is what I call the next step. And this is represented by the blue arrow, which is, of course, a very important aspect of our clinical development program. Now we have a dose, we have a schedule, and we can move forward. Regarding the final results of the CORIST study, we do not expect them before H1 2025 because the data need time to mature. The data need to mature, giving a chance to the patients, some of whom are still surviving, and therefore we do expect to release some encouraging overall survival data. The next step would be a randomized clinical trial, either a Phase 2B or a Phase 3 directly. For that purpose, we need to have a partner. We are a small company and thus, need to embark on such a journey. So, we need to have more financial muscle in order to do it. That's the reason why, you have seen, I'm sure, the press release that announces the appointment of Back Bay as a boutique financial firm to help find a partner, for moving forward with the pancreatic data path. We do not expect anything different from what has been published recently. And again, mainly for prioritization. For prioritization, we believe that focusing on colorectal cancer is the right way to go. This is where we have the highest chance of success. These include other indications like pancreatic and gastric cancers. Right, next slide please. To sum up this brief conference call, but still very important, because it's the first time in the history of Scandion Oncology that we have shown we have an MTD, establishing a viable dose. Thus, we remain one of the first movers in combating drug resistance. We are an export inhibition company, leveraging this dual mechanism of action that we addressed in previous conference calls, targeting two biomarkers. We are working in areas of high unmet medical needs. Colorectal cancer at the metastatic stage has a very poor survival rate of around 12%. We believe we can significantly aid patients. We can certainly provide an alternative to the current standard of care in the future. And indeed, we have been able to demonstrate this in the preliminary open-label data. Phase one and phase two indicate that we have an effective drug which has broad commercial potential down the road, and also in some indications as well. So, when you review the cash management practices we have been able to implement up till now, we will continue to be extremely focused, and we will work with our newly appointed partner, Back Bay, which, as I said, is a Boston-based boutique firm. Having said that, we will be communicating at the right time when we have some further data with regard to cohort three, the final cohort, and also the last patients that we have enrolled into what we call the list. Next step, in order to hopefully show that we have good efficacy data. Right, having said that, um. Next slide, please. Having said that, I re-emphasized the fact that we are in a good position, the most favorable position in the history of medicine. We have been able to demonstrate some efficacy data with our compound. We've been able to demonstrate good safety, good tolerability, and we have been able to close the study on time, even ahead of schedule. Actually, looking ahead to the next step, we are potentially seeking a partner and are ready to take any questions you may have.

Operator
13:56 - 14:06

If you wish to ask a question, please dial pound key five on your telephone keypad. The first question is from Christian Binder from Redeye. Please go ahead.

Chris
14:10 - 14:30

Hi, and thanks so much for taking my question. I just have one quick question regarding the increased partnering efforts. Can you provide any more details on what kind of partnerships you are considering? And, um, what kind of timeline should we be looking at in terms of when we will receive this?

Francois Martelet, MD
14:32 - 15:10

Right. Thank you for your question, Chris. Uh, well, obviously I can discuss this further, but we are certainly looking at big pharmaceutical companies, as well as biotech companies ranging from small to mid-size, in order to provide us with the necessary financial resources to conduct a randomized clinical trial. All options are open, and we are certainly also looking at potential financial alternatives, such as fundraising.

Chris
15:14 - 15:15

Thank you so much. That was all for my son.

Francois Martelet, MD
15:15 - 15:16

You're welcome.

Operator
15:18 - 15:24

There are no more questions from the teleconference, so they hand the word back to you for closing remarks.

Unknown 1
15:27 - 15:28

Yes.

Francois Martelet, MD
15:28 - 15:58

So I just would like to thank you. Our shareholders have been through some difficult times recently. We are very excited to move to the next step as a company because we have been able to achieve this long first step, which is to basically enroll and get the data in a Phase 2A, and certainly very excited to move to the next step. And I hope you feel the same. Thank you again.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…